Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Regulatory Affairs
• Regenerative Medicine

Background:

• Advanced therapy medicinal products (ATMPs) represent a novel class of medicines in the European Union, necessitating a specialized regulatory framework established in 2009.
• The Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA) centralizes classification, certification, and evaluation of ATMPs.
• Resources like guidance documents and interaction platforms are available to assist developers, particularly small- and medium-sized enterprises, academia, and hospitals.

Purpose of the Study:

• To provide an overview of the regulatory landscape for ATMPs in the EU.
• To guide cell therapy developers, especially those working with mesenchymal stem cells (MSCs), through the development and authorization process.
• To highlight the importance of engaging with regulatory resources from the pre-clinical stage.

Main Methods:

• Review of the European Union's regulatory framework for ATMPs.
• Analysis of the role and functions of the Committee for Advanced Therapies (CAT).
• Examination of available support mechanisms and initiatives for ATMP developers.

Main Results:

• The EU has a dedicated regulatory system for ATMPs, operational since 2009, with the CAT playing a central role.
• While no MSC-based ATMPs have been authorized in the EU, three such products received marketing approval in other regions after 2011.
• Various resources and platforms exist to facilitate the development and regulatory navigation for ATMP innovators.

Conclusions:

• A thorough understanding of the EU's centralized and national regulatory components is essential for successful ATMP product development.
• Early engagement with regulatory authorities and utilization of available resources can significantly streamline the path to market authorization for cell therapies.
• The regulatory framework aims to foster innovation in advanced therapies, including promising MSC-based treatments.